A phase 2 study of bortezomib in relapsed, refractory myeloma.
Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC.
Richardson PG, et al. Among authors: barlogie b.
N Engl J Med. 2003 Jun 26;348(26):2609-17. doi: 10.1056/NEJMoa030288.
N Engl J Med. 2003.
PMID: 12826635
Free article.
Clinical Trial.